Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2007
11/21/2007EP1856126A2 Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
11/21/2007EP1856114A1 Benzisoxazole derivatives
11/21/2007EP1856107A1 Pyrrolidine and piperidine acetylene derivatives for use as mglur5 antagonists
11/21/2007EP1856100A2 Cgrp receptor antagonists
11/21/2007EP1856077A1 Piperazine derivatives as glyt1 inhibitors
11/21/2007EP1856076A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
11/21/2007EP1856071A1 Benzoxazocines and their therapeutic use
11/21/2007EP1856052A2 Nk1 antagonists
11/21/2007EP1855686A1 Use of pde7 inhibitors for the treatment of neuropathic pain
11/21/2007EP1855679A2 Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
11/21/2007EP1855677A1 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
11/21/2007EP1855673A2 Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
11/21/2007EP1855670A2 Benzazole potentiators of metabotropic glutamate receptors
11/21/2007EP1855663A2 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
11/21/2007EP1855661A1 Formulation for aviptadil
11/21/2007EP1855657A2 Dosage form containing oxycodone and naloxone
11/21/2007EP1761524B1 Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine d3 antagonists
11/21/2007EP1718340B1 New effector conjugates, process for their production and their pharmaceutical use
11/21/2007EP1697378B1 Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
11/21/2007EP1623711B1 External patch containing estrogen and/or progestogen
11/21/2007EP1578425B1 Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
11/21/2007EP1572653B1 Saturated and unsaturated heteroarylcycloalkylmethyl amines as anti-depressants
11/21/2007EP1563852B1 Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils
11/21/2007EP1482920B1 Compositions containing n-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
11/21/2007EP1474140B1 2-oxazolamines and their use as 5-ht2b receptor antagonists
11/21/2007EP1474139B1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/21/2007EP1458383B1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
11/21/2007EP1458368B1 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
11/21/2007EP1455777B1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/21/2007EP1421062B1 Novel cyclohexyl sulphones
11/21/2007EP1405639B1 Use of sodium channel blocking compounds and aspirin in manufacturing drugs for producing synergistic analgesic effect in mammals
11/21/2007EP1370150B1 One-step process for preparing chewing gum
11/21/2007EP1319064B1 Gsk3 polypeptides
11/21/2007EP1315515B1 Method for treating schizophrenia and related psychoses, and the use of erythropoietin or erythropoietin derivatives for treating schizophrenic disorders and related psychoses
11/21/2007EP1301500B1 Nitrosated and nitrosylated taxanes, compositions and methods of use
11/21/2007EP1269196B1 Method of screening for inhibitors of osteopontin
11/21/2007EP1197226B1 Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
11/21/2007EP1188445B1 Drug composition containing lecithin-modified superoxide dismutase
11/21/2007EP0522091B9 Use of a mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
11/21/2007CN101076543A Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
11/21/2007CN101076539A Crystal and deforming shaped smilagenin
11/21/2007CN101076532A Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease.
11/21/2007CN101076527A Tricyclic anilide spirohydantoin cgrp receptor antagonists
11/21/2007CN101076526A Tricyclic guanidine derivatives as sodium-proton exchange inhibitors
11/21/2007CN101076517A Substituted piperidines as modulators of dopamine neurotransmission
11/21/2007CN101076340A GABA-steroid antagonists and their use for the treatment of cns disorders
11/21/2007CN101076339A Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neurodegenerative disorders
11/21/2007CN101076336A Novel curcumin analogues and uses thereof
11/21/2007CN101076328A Preventive or therapeutic agent for sleep disorder
11/21/2007CN101076327A Carbamate compounds for use in treating neurodegenerative disorders
11/21/2007CN101076325A Medicinal composition of edible carboxylic-acid and/or its acid salts and caffeine and non-drug addiction coffee
11/21/2007CN101074200A Aspartic acid salt of O-demethyl-Venlafacin
11/21/2007CN101073666A Method for producing high-purity kallidin proenzyme raw-material medicine
11/21/2007CN101073647A Medicinal composition for treating chronic cephalalgia and its making method
11/21/2007CN101073646A Method for treating tic douloureux
11/21/2007CN101073634A Pill for treating dementia praecox
11/21/2007CN101073617A Use of medicinal composition in treatment of micro-circulation handicap and prevention of stroke
11/21/2007CN101073613A Method for treating nervous prostration
11/21/2007CN101073607A Chinese patent drug for treating epilepsy
11/21/2007CN101073584A Method and compositions for altering cell function
11/21/2007CN101073406A Efficient smoke-stopping oral liquid and its production
11/21/2007CN101073405A Lung-moistening and smoke-stopping beverage and its production
11/21/2007CN101073367A Candy for refraining from smoking and its production
11/21/2007CN101073351A Memory-enhancing tea with brain-invigorating and vision-improving functions
11/21/2007CN101073346A Efficient smoke-refraining tea and its production
11/21/2007CN100349874C Novel compounds
11/21/2007CN100349872C Method for producing amine derivative
11/21/2007CN100349856C Propionic acid derivatives and their use as hPPARs activators
11/21/2007CN100349567C (-)-epigallocatechin gallate-magnesium complex solid dispersion and its prepn and application
11/20/2007US7297820 Thio substituted stilbene amines; inhibiting the aggregation of amyloid proteins
11/20/2007US7297818 Adamantane derivatives
11/20/2007US7297799 Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof
11/20/2007US7297792 Pyrazolopyridines and pyrazolopyridazines as antidiabetics
11/20/2007US7297790 Anhydrous mirtazapine crystals and process for preparing the same
11/20/2007US7297789 From 4-amino-2-methyl-10H-thieno(2,3-b)(1,5) benzodiazpine HCl and 1-methylpiperazine in an aprotic high boiling solvent; purifying in an acid medium; basifying to pH of 7.5-9; and extracting with a low boiling organic solvent
11/20/2007US7297771 Polypeptides having opioid receptor activity
11/20/2007US7297763 Mixture of IGF-1 and N,N-bis(3-D-gluconamidopropyl)-deoxycholamine that binds specifically to IGF-1 and blocks binding of IGFBP-1 and IGFBP-3; used as a standard for identifying IGF-1 indirect agonists
11/20/2007US7297715 PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
11/20/2007US7297711 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
11/20/2007US7297708 Central nervous system disorders; psychological disorders
11/20/2007US7297705 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
11/20/2007US7297699 Piperazine and piperidine compounds
11/20/2007US7297694 central nervous system disorders; traumas; anticancer agents; neurodegenerative agents; analgesics; headaches and cardiovascular disorders
11/20/2007US7297693 furan-, pyrrole- or thiophenecarboxamides ring-substituted with a hydroxyimino-fused ring and a nitrogen heteroarene; e.g., 5-[5-(1-Morpholin-4-yl-methanoyl)-2-pyridin-4-yl-furan-3-yl]-indan-1-one oxime;treating neurotraumatic diseases, cancer, neurodegeneration, pain, migraine and cardiac hypertrophy
11/20/2007US7297692 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them
11/20/2007US7297691 Administering galanthamine and nicotinic receptors
11/20/2007US7297523 Human elongase genes and uses thereof
11/20/2007US7297346 For therapy of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain attention deficit hyperactivity disorder and fatigue
11/20/2007US7297334 Anti-vegf antibodies
11/20/2007US7297099 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/20/2007CA2328197C Methods for treating neuropsychiatric disorders
11/20/2007CA2305598C Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects
11/20/2007CA2216372C Oral 2-methyl-thieno-benzodiazepine formulation
11/15/2007WO2007131154A2 Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
11/15/2007WO2007131020A2 Constrained compounds as cgrp-receptor antagonists
11/15/2007WO2007130927A2 Condensed tricyclic compounds as cgrp-receptor antagonists
11/15/2007WO2007130860A2 Constrained compounds as cgrp-receptor antagonists
11/15/2007WO2007130825A2 Fused heterocyclic compounds and their use as mglur5 modulators
11/15/2007WO2007130823A2 Polycyclic heterocyclic compounds and their use as modulators of the metabotropic glutamate 5 receptor
11/15/2007WO2007130822A2 Mglur5 modulators iii
1 ... 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 ... 1833